Abstract
Despite promising results following implementation of neoadjuvant chemoradiation (nCRT) prior to surgery in resectable esophageal adenocarcinoma (EAC) (van Hagen et al., NEJM, 2012) and the introduction of adjuvant nivolumab in case of incomplete response (Kelly et al., NEJM, 2021), prognosis remains dismal. Many patients eventually develop metastatic disease, and there is an unmet need to improve current therapies. In 15% to 43% of EAC cases, overexpression and/or gene amplification of the human epidermal growth factor receptor 2 (HER2) is observed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
